<DOC>
	<DOCNO>NCT00887575</DOCNO>
	<brief_summary>This trial examine combination sunitinib plus paclitaxel carboplatin neoadjuvant treatment locally advance breast cancer .</brief_summary>
	<brief_title>Neoadjuvant Sunitinib With Paclitaxel/Carboplatin Patients With Triple-Negative Breast Cancer</brief_title>
	<detailed_description>This open label , Phase I/II trial design evaluate combination sunitinib plus paclitaxel carboplatin neoadjuvant treatment locally advance breast cancer . The Phase I portion study determine maximum tolerate dose ( MTD ) paclitaxel , sunitinib carboplatin use together neoadjuvant treatment patient locally advance breast cancer . The MTD identify Phase I portion study use Phase II portion evaluate efficacy , safety , tolerability neoadjuvant sunitinib/paclitaxel/carboplatin give 6 cycle patient locally advance breast cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Female patient , age ≥18 year 2 . Histologically confirm invasive ER , PR , HER2negative ( triplenegative ) adenocarcinoma breast 3 . Triplenegative tumor define : For HER2negative : Fluorescence situ hybridization ( FISH ) negative ( define ratio &lt; 2.2 ) OR Immunohistochemical ( IHC ) 0 , IHC 1+ , OR IHC 2+ IHC 3+ FISHnegative ( define ratio &lt; 2.2 ) For ER PRnegative : &lt; 10 % tumor stain immunohistochemistry ( IHC ) 4 . Primary palpable disease confine breast axilla physical examination . For patient without clinically suspicious axillary adenopathy , primary tumor must large 2 cm diameter physical exam image study ( clinical T2T3 , N0N1 , M0 ) . For patient clinically suspicious axillary adenopathy , primary breast tumor size ( clinical T13 , N12 , M0 ) . T1N0M0 lesion exclude . Patients metastatic disease exclude . 5 . Patients without clearly define palpable breast mass axillary lymph node radiographically measurable tumor mass eligible . Accepted procedure measure breast disease mammography , MRI , breast ultrasound . Patients lesion measurable image require repeat image 3 cycle prior surgery 6 . Eastern Cooperative Oncology Group performance status ( ECOG PS ) 02 7 . Neuropathy grade &lt; 1 Common Terminology Criteria Adverse Events version 3.0 ( CTCAE v 3.0 ) 8 . Resolution acute effect surgical procedure grade ≤1 . For patient , sentinel lymph node and/or axillary dissection prior initiation study treatment , completion least 4 week prior start study treatment wellhealed wound require 9 . Adequate hematologic function : Absolute neutrophil count ( ANC ) &gt; 1500/μL Platelets ≥100,000/μL Hemoglobin ≥10 g/dL 10 . Adequate hepatic renal function : Serum bilirubin ≤ institutional upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤2.5 x institutional ULN Alkaline phosphatase ≤2.5 x institutional ULN Serum creatinine ≤1.5 x ULN calculate creatinine clearance ≥40 mL/min 11 . Left ventricular ejection fraction ( LVEF ) ≥50 % multigated acquisition ( MUGA ) echocardiogram ( ECHO ) 12 . Bilateral , synchronous breast cancer allow one primary tumor meet inclusion criterion 13 . Knowledge investigational nature study ability provide consent study participation 14 . Ability willingness comply study visit , treatment , test , study procedure 1 . Previous treatment breast cancer 2 . Previous treatment paclitaxel carboplatin 3 . Previous treatment sunitinib angiogenic inhibitor ( include , limited bevacizumab , sorafenib , thalidomide ) 4 . Any follow within 12 month prior start study treatment : myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , congestive heart failure , cerebrovascular accident include transient ischemic attack , pulmonary embolus 5 . Uncontrolled hypertension ( blood pressure &gt; 150/100 mmHg despite optimal medical therapy ) 6 . Ongoing cardiac dysrhythmias grade ≥2 , atrial fibrillation grade , prolongation QTc interval &gt; 470 msec 7 . Major surgery , significant traumatic injury , radiation therapy within 4 week start study treatment . An interval least 1week require follow minor surgical procedure , exception placement vascular access device 8 . Grade 3 hemorrhage within 4 week start study treatment 9 . Preexisting thyroid abnormality thyroid function maintain normal range medication 10 . Known human immunodeficiency virus ( HIV ) infection serious infection 11 . Concomitant treatment drug proarrhythmic potential include terfenadine , quinidine , procainamide , disopyramide , sotalol , probucol , bepridil , haloperidol , risperidone , indapamide , flecainide 12 . Concurrent use potent CYP3A4 inhibitor ketoconazole , itraconazole , clarithromycin , atazanavir , nefazodone , saquinavir , telithromycin , ritonavir , amprenavir , indinavir , nelfinavir , delavirdine voriconazole CYP3A4 inducer rifampin , rifabutin , rifapentine , phenobarbital , phenytoin , carbamazepine , St. John 's Wort , dexamethasone . Use dexamethasone study premedication allow . Grapefruit grapefruit juice prohibit . Alternative therapy use available . If use potent CYP3A4 inhibitor inducer necessary , must approve Study Chair 13 . Known suspected hypersensitivity drug contain Cremophor®EL ( polyoxyethylated castor oil ) cyclosporine teniposide 14 . Pregnancy breastfeed . Negative serum pregnancy test require within 7 day prior first study treatment ( Day 1 , Cycle ) woman childbearing potential . Patients childbearing potential must agree use birth control method approve study physician receive study treatment three month last dose study treatment . Patients must agree breastfeed receive study treatment 15 . Concurrent treatment ovarian hormonal replacement therapy hormonal agent raloxifene , tamoxifen selective estrogen receptor modulator ( SERM ) . Patients must discontinue use agent prior begin study treatment 16 . History malignancy treat curative intent within previous 5 year exception skin cancer , cervical carcinoma situ , follicular thyroid cancer . Patients previous invasive cancer ( include breast cancer ) eligible treatment complete 5 year prior initiate current study treatment , evidence recurrent disease 17 . Use investigational agent within 30 day administration first dose study drug concurrent treatment another clinical study 18 . Requirement radiation therapy concurrent study anticancer treatment . Patients require breast chest wall radiation therapy surgery eligible , maintenance sunitinib interrupt receive radiation 19 . Any disease ( ) , psychiatric condition , metabolic dysfunction , finding physical examination clinical laboratory test result would cause reasonable suspicion disease condition , contraindicate use study drug , may increase risk associate study participation , may affect interpretation result , would make patient inappropriate study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Triple-Negative</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Sunitinib</keyword>
	<keyword>Sutent</keyword>
	<keyword>Neoadjuvant</keyword>
</DOC>